128 related articles for article (PubMed ID: 38284208)
21. Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.
Sbidian E; Chaimani A; Garcia-Doval I; Doney L; Dressler C; Hua C; Hughes C; Naldi L; Afach S; Le Cleach L
Cochrane Database Syst Rev; 2021 Apr; 4(4):CD011535. PubMed ID: 33871055
[TBL] [Abstract][Full Text] [Related]
22. Dietary lysophosphatidylcholine regulates diacylglycerol, cardiolipin and free fatty acid contents in the fillet of turbot.
Xu H; Luo X; Wei Y; Liang M
Food Chem X; 2022 Jun; 14():100293. PubMed ID: 35356697
[TBL] [Abstract][Full Text] [Related]
23. Biologic and Conventional Systemic Therapies Show Similar Safety and Efficacy in Elderly and Adult Patients With Moderate to Severe Psoriasis.
Garber C; Plotnikova N; Au SC; Sorensen EP; Gottlieb A
J Drugs Dermatol; 2015 Aug; 14(8):846-52. PubMed ID: 26267729
[TBL] [Abstract][Full Text] [Related]
24. Long-Term Treatment Patterns Among Patients With Psoriasis Treated With Ixekizumab or Adalimumab: A Real-World Study.
Blauvelt A; Shi N; Murage M; Ridenour T; Lew C; Somani N; Zhu B; Zimmerman N; Kern S; Burge R
J Drugs Dermatol; 2022 Apr; 21(4):399-407. PubMed ID: 35389589
[TBL] [Abstract][Full Text] [Related]
25. Network meta-analyses comparing the efficacy of biologic treatments for achieving complete resolution of nail psoriasis at 24-28 and 48-52 weeks.
Egeberg A; Kristensen LE; Puig L; Rich P; Smith SD; Garrelts A; See K; Holzkaemper T; Fotiou K; Schuster C
J Dermatolog Treat; 2023 Dec; 34(1):2263108. PubMed ID: 37781881
[TBL] [Abstract][Full Text] [Related]
26. Comparative effectiveness of biologics in clinical practice: week 12 primary outcomes from an international observational psoriasis study of health outcomes (PSoHO).
Pinter A; Puig L; Schäkel K; Reich A; Zaheri S; Costanzo A; Tsai TF; Smith SD; Lynde C; Brnabic A; Reed C; Hill J; Schuster C; Riedl E; Paul C
J Eur Acad Dermatol Venereol; 2022 Nov; 36(11):2087-2100. PubMed ID: 35766124
[TBL] [Abstract][Full Text] [Related]
27. Efficacy and safety of biologics in erythrodermic psoriasis: a multicentre, retrospective study.
Viguier M; Pagès C; Aubin F; Delaporte E; Descamps V; Lok C; Beylot-Barry M; Séneschal J; Dubertret L; Morand JJ; Dréno B; Bachelez H;
Br J Dermatol; 2012 Aug; 167(2):417-23. PubMed ID: 22413927
[TBL] [Abstract][Full Text] [Related]
28. A head-to-head comparison of the efficacy and safety of ixekizumab and adalimumab in biological-naïve patients with active psoriatic arthritis: 24-week results of a randomised, open-label, blinded-assessor trial.
Mease PJ; Smolen JS; Behrens F; Nash P; Liu Leage S; Li L; Tahir H; Gooderham M; Krishnan E; Liu-Seifert H; Emery P; Pillai SG; Helliwell PS;
Ann Rheum Dis; 2020 Jan; 79(1):123-131. PubMed ID: 31563894
[TBL] [Abstract][Full Text] [Related]
29. Biologic treatment sequences for plaque psoriasis: a cost-utility analysis based on 10 years of Dutch real-world evidence from BioCAPTURE.
Klijn SL; van den Reek JMPA; van de Wetering G; van der Kolk A; de Jong EMGJ; Kievit W
Br J Dermatol; 2018 May; 178(5):1181-1189. PubMed ID: 29247500
[TBL] [Abstract][Full Text] [Related]
30. QuantiFERON TB-gold conversion rate among psoriasis patients under biologics: a 9-year retrospective study.
Megna M; Ferrillo M; Ruggiero A; Cinelli E; Gallo L; Fabbrocini G
Int J Dermatol; 2021 Mar; 60(3):352-357. PubMed ID: 32989759
[TBL] [Abstract][Full Text] [Related]
31. Phosphatidylcholine and phosphatidylethanolamine plasmalogens in lipid loaded human macrophages.
Wallner S; Orsó E; Grandl M; Konovalova T; Liebisch G; Schmitz G
PLoS One; 2018; 13(10):e0205706. PubMed ID: 30308051
[TBL] [Abstract][Full Text] [Related]
32. Lipidomic analysis of plasma lipids composition changes in septic mice.
Ahn WG; Jung JS; Song DK
Korean J Physiol Pharmacol; 2018 Jul; 22(4):399-408. PubMed ID: 29962854
[TBL] [Abstract][Full Text] [Related]
33. [Treatment of plaque psoriasis with biologics. A meta-analysis of randomized controlled trials].
Zhang Z; Schmitt J; Wozel G; Kirch W
Med Klin (Munich); 2009 Feb; 104(2):125-36. PubMed ID: 19242664
[TBL] [Abstract][Full Text] [Related]
34. Dose escalation and associated costs in biologic treatment of psoriasis based on real-world data.
Bagel J; Glick B; Wu JJ; Chopra I; Song X; Brouillette M; Mendelsohn A; Rozzo S; Han G
J Med Econ; 2021; 24(1):782-791. PubMed ID: 34107834
[TBL] [Abstract][Full Text] [Related]
35. Cost per responder of biologic drugs used in the treatment of moderate-to-severe plaque psoriasis in France and Germany.
Nyholm N; Schnack H; Danø A; Skowron F
Curr Med Res Opin; 2023 Jun; 39(6):833-842. PubMed ID: 37203343
[TBL] [Abstract][Full Text] [Related]
36. Real-world treatment patterns and healthcare costs among biologic-naive patients initiating apremilast or biologics for the treatment of psoriasis.
Wu JJ; Pelletier C; Ung B; Tian M
J Med Econ; 2019 Apr; 22(4):365-371. PubMed ID: 30652520
[TBL] [Abstract][Full Text] [Related]
37. Adalimumab in the treatment of moderate-to-severe chronic plaque psoriasis in patients switching from other biologics.
Sator P; Richter L; Saxinger W; Vasiljevic M; Stingl G
J Eur Acad Dermatol Venereol; 2015 Sep; 29(9):1742-9. PubMed ID: 25665143
[TBL] [Abstract][Full Text] [Related]
38. Treatment outcomes with ixekizumab in patients with moderate-to-severe psoriasis who have or have not received prior biological therapies: an integrated analysis of two Phase III randomized studies.
Gottlieb AB; Lacour JP; Korman N; Wilhelm S; Dutronc Y; Schacht A; Erickson J; Zhang L; Mallbris L; Gerdes S
J Eur Acad Dermatol Venereol; 2017 Apr; 31(4):679-685. PubMed ID: 27696577
[TBL] [Abstract][Full Text] [Related]
39. Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.
Sbidian E; Chaimani A; Afach S; Doney L; Dressler C; Hua C; Mazaud C; Phan C; Hughes C; Riddle D; Naldi L; Garcia-Doval I; Le Cleach L
Cochrane Database Syst Rev; 2020 Jan; 1(1):CD011535. PubMed ID: 31917873
[TBL] [Abstract][Full Text] [Related]
40. Patient Preference for Dosing Frequency Based on Prior Biologic Experience.
Zhang M; Carter C; Olson WH; Johnson MP; Brennem SK; Lee S; Farahi K
J Drugs Dermatol; 2017 Mar; 16(3):220-226. PubMed ID: 28301617
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
